Memantine and NMDA antagonism for chronic migraine: A potentially novel therapeutic approach?

Headache

Volumn 48, Issue 2, 2008, Pages 284-286

  Spengos, Konstantinos ^a   Theleritis, Christos ^a   Paparrigopoulos, Thomas ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Chronic migraine; Memantine; NMDA receptor; Prophylaxis

Indexed keywords

MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT;

AGED; ARTICLE; CASE REPORT; COGNITIVE DEFECT; DOSE RESPONSE; DRUG TOLERANCE; FEMALE; HEADACHE; HUMAN; MINI MENTAL STATE EXAMINATION; NEUROPSYCHOLOGICAL TEST; PRIORITY JOURNAL; REMISSION; TRANSFORMED MIGRAINE;

AGED; CHRONIC DISEASE; COGNITION DISORDERS; DOSE-RESPONSE RELATIONSHIP, DRUG; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; HUMANS; MEMANTINE; MIGRAINE DISORDERS;

EID: 38749110015     PISSN: 00178748     EISSN: 15264610     Source Type: Journal    
DOI: 10.1111/j.1526-4610.2007.01016.x     Document Type: Article

References (16)

1. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgia and facial pain. Cephalalgia. 1988 8 (Suppl. 1 1 96.
2. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgia and facial pain. Cephalalgia. 2004 24 (Suppl. 1 1 160.
3. Spierings EL, Ranke AH, Schroevers M, Honkoop PC. Chronic daily headache: A time perspective. Headache. 2000 40 : 306 310.
4. Bigal ME, Rapaport AM, Sheftell FD, Tepper SJ, Lipton R. Chronic migraine is an earlier stage of transformed migraine in adults. Neurology. 2005 65 : 1556 1561.
5. Bigal ME, Rapaport AM, Sheftell FD, Tepper SJ, Lipton R. Chronic daily headache in a tertiary care population: Correlation between the International Headache Society diagnostic criteria and proposed revisions of criteria of chronic daily headache. Cephalalgia. 2002 22 : 432 438.
6. Mathew NT. The prophylactic treatment of chronic daily headache. Headache. 2006 46 : 1552 1564.
7. Demeaschalk BM, Wingerchuk DM. Treatment of vascular dementia and vascular cognitive impairment. Neurologist. 2007 13 : 37 41.
8. Lipton SA. Pathologically-activated therapeutics for neuroprotection: Mechanism of NMDA receptor block by memantine and S-nitrosylation. Curr Drug Targets. 2007 8 : 621 632.
9. Warncke T, Stubhaug A, Jorum E. Preinjury treatment with morphine or ketamine inhibits the development of experimentally induced secondary hyperalgesia in man. Pain. 1996 86 : 293 303.
10. Wiech K, Kiefer RT, Topfner S, et al. A placebo-controlled randomized crossover trial of the N-methyl-D-aspartic acid receptor antagonist, memantine, in patients with chronic phantom limb pain. Anesth Analg. 2004 98 : 408 413.
11. Sinis N, Birbaumer N, Gustin S, et al. Memantine treatment of complex regional pain syndrome. A preliminary report of six cases. Clin J Pain. 2007 23 : 237 243.
12. Block F, Habermeyer B. Glutamate antagonists for treatment of neuropathic pain. Schmerz. 2003 17 : 261 267.
13. Cammarata D, Krusz JC. Memantine: Novel mechanism for migraine and headache prophylaxis. Headache. 2005 45 : 820.
14. Peeters M, Gunthorpe MJ, Strijbos PJ, Goldsmith P, Upton N, James MF. Effects of pan- and subtype-selective N-methyl-D-aspartate receptor antagonists on cortical spreading depression in the rat: Therapeutic potential for migraine. J Pharmacol Exp Ther. 2007 321 : 564 572.
15. Kaube H, Herzog J, Kaufer T, Dichgans M, Diener HC. Aura in some patients with familial hemiplegic migraine can be stopped by intranasal ketamine. Neurology. 2000 55 : 139 141.
16. Ramadan NM. The link between glutamate and migraine. CNS Spectr. 2004 3 : 446 449.